[go: up one dir, main page]

MX2009011619A - Formulaciones que contienen clopidogrel y eter sulfoalquilico-ciclodextrina y metodos de uso. - Google Patents

Formulaciones que contienen clopidogrel y eter sulfoalquilico-ciclodextrina y metodos de uso.

Info

Publication number
MX2009011619A
MX2009011619A MX2009011619A MX2009011619A MX2009011619A MX 2009011619 A MX2009011619 A MX 2009011619A MX 2009011619 A MX2009011619 A MX 2009011619A MX 2009011619 A MX2009011619 A MX 2009011619A MX 2009011619 A MX2009011619 A MX 2009011619A
Authority
MX
Mexico
Prior art keywords
sae
clopidogrel
compositions
liquid
degradation
Prior art date
Application number
MX2009011619A
Other languages
English (en)
Inventor
Gerold L Mosher
Karen T Johnson
Rebecca L Wedel
Stephen G Machatha
Jane A Cowee
Daniel J Cushing
Original Assignee
Cydex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cydex Pharmaceuticals Inc filed Critical Cydex Pharmaceuticals Inc
Publication of MX2009011619A publication Critical patent/MX2009011619A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

La presente invención proporciona composiciones que contienen clopidogrel, presente como una base libre o como una sal farmacéuticamente aceptable del mismo, y éter sulfoalquílico-ciclodextrina (SAE-CD). Las composiciones pueden ser composiciones líquidas, en suspensión o sólidas. Pueden estar adaptadas para la administración oral, peroral o parenteral. La SAE-CD sirve para ayudar en la disolución y estabilización del clopidogrel en medios acuosos. Se mejora la estabilidad del clopidogrel contra la degradación hidrolítica, degradación térmica y degradación fotolítica. La SAE-CD proporciona resultados mejorados sobre otros derivados de ciclodextrina. La composición de clopidogrel que contiene SAE-CD se puede proporcionar en forma líquida, forma sólida o como un polvo reconstituible. Se pueden preparar composiciones líquidas tanto listas para su uso como concentradas. La composición líquida está disponible opcionalmente como una solución clara. Las composiciones en este documento se pueden administrar por la ruta peroral o parenteral y pueden proporcionar ventajas farmacocinéticas, farmacodinámicas y/o terapéuticas sustanciales sobre una composición en forma de tableta que es administrada por la ruta peroral y que excluye la SAE-CD.
MX2009011619A 2007-04-27 2008-04-26 Formulaciones que contienen clopidogrel y eter sulfoalquilico-ciclodextrina y metodos de uso. MX2009011619A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91455507P 2007-04-27 2007-04-27
PCT/US2008/061697 WO2008134600A1 (en) 2007-04-27 2008-04-26 Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use

Publications (1)

Publication Number Publication Date
MX2009011619A true MX2009011619A (es) 2010-01-18

Family

ID=39926106

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009011619A MX2009011619A (es) 2007-04-27 2008-04-26 Formulaciones que contienen clopidogrel y eter sulfoalquilico-ciclodextrina y metodos de uso.

Country Status (17)

Country Link
US (6) US8343995B2 (es)
EP (2) EP2152078B8 (es)
JP (4) JP5681485B2 (es)
KR (3) KR101753131B1 (es)
CN (2) CN104800210B (es)
AU (1) AU2008245550B2 (es)
BR (1) BRPI0809838B1 (es)
CA (2) CA2921601C (es)
DK (1) DK2152078T3 (es)
ES (1) ES2855700T3 (es)
HU (1) HUE053158T2 (es)
IL (1) IL201776A (es)
MX (1) MX2009011619A (es)
NZ (1) NZ581362A (es)
RU (1) RU2470636C2 (es)
SI (1) SI2152078T1 (es)
WO (2) WO2008134600A1 (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170123724A (ko) 2006-03-28 2017-11-08 자블린 파머슈티칼스 인코포레이티드 저 투여량의 디클로페낙 및 베타-사이클로덱스트린 제형
RU2470636C2 (ru) * 2007-04-27 2012-12-27 Сайдекс Фамэсьютиклз, Инк. Композиция клопидогреля и сульфоалкилового эфира циклодекстрина (варианты) и способы лечения заболеваний посредством названной композиции (варианты)
WO2009128730A1 (en) * 2008-01-25 2009-10-22 Patrick Gladding Methods and compositions for the assessment of drug response
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
WO2009133455A2 (en) * 2008-05-01 2009-11-05 Cadila Healthcare Limited Pharmaceutical composition of clodipogrel
US9427448B2 (en) * 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
FR2932387B1 (fr) * 2008-06-16 2010-09-17 Cll Pharma Composition orale contenant un agent anti-plaquettaire de la famille des thienopyridines sous forme de base.
WO2010053487A1 (en) 2008-11-07 2010-05-14 Cydex Pharmaceuticals, Inc. Composition containing sulfoalkyl ether cyclodextrin and latanoprost
DK3100728T3 (da) * 2009-05-13 2020-02-17 Cydex Pharmaceuticals Inc Farmaceutiske sammensætninger omfattende prasugrel og cyclodextrin-derivativ og fremgangsmåder til fremstilling og brug af samme
US7803762B1 (en) 2009-08-20 2010-09-28 The Medicines Company Ready-to-use bivalirudin compositions
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
WO2011060066A2 (en) 2009-11-11 2011-05-19 The Medicines Company Methods of treating or preventing stent thrombosis
US8563574B2 (en) * 2009-12-07 2013-10-22 Academic Pharmaceuticals, Inc. Parenteral formulation of clopidogrel
WO2011101865A2 (en) * 2010-02-19 2011-08-25 Cadila Healthcare Limited Stable pharmaceutical compositions of clopidogrel for parenteral delivery
CN102232949A (zh) * 2010-04-27 2011-11-09 孙远 提高药物溶出度的组合物及其制备方法
WO2012122493A1 (en) * 2011-03-10 2012-09-13 Jina Pharmaceuticals, Inc. Lipid based clopidogrel compositions, methods, and uses
RU2014127884A (ru) * 2011-12-09 2016-02-10 Вокхардт Лимитед Способы лечения сердечно-сосудистого нарушения
CA2861077A1 (en) * 2012-01-30 2013-08-08 Baxter International Inc. Non-anticoagulant sulfated or sulfonated polysaccharides
US9009933B2 (en) * 2012-02-02 2015-04-21 Astrid Lombardi Method to improve the appearance of a corpse and new thanatocosmetic compositions
US9751957B2 (en) 2012-02-15 2017-09-05 Cydex Pharmaceuticals, Inc. Manufacturing process for cyclodextrin derivatives
KR20160033795A (ko) 2012-02-28 2016-03-28 사이덱스 파마슈티칼스, 인크. 알킬화된 시클로덱스트린 조성물 및 이의 제조 및 사용 방법
KR102112119B1 (ko) 2012-10-22 2020-05-19 사이덱스 파마슈티칼스, 인크. 알킬화된 시클로덱스트린 조성물 및 이의 제조 및 사용 방법
KR102238292B1 (ko) * 2013-02-06 2021-04-09 징준 후앙 경구 및 비경구적 전달을 위한 클로피도그렐 유리 염기의 안정한 약학 조성물
CN110186835B (zh) 2013-03-15 2022-05-31 Gpb科学有限公司 颗粒的片上微流体处理
US20150064153A1 (en) 2013-03-15 2015-03-05 The Trustees Of Princeton University High efficiency microfluidic purification of stem cells to improve transplants
JP2016513699A (ja) * 2013-03-15 2016-05-16 エピザイム，インコーポレイティド 癌の治療のための注射製剤
EP3608022A1 (en) 2013-03-15 2020-02-12 The Trustees of Princeton University Methods and devices for high throughput purification
EP3521442B1 (en) 2013-07-15 2023-05-03 President and Fellows of Harvard College Assays for antimicrobial activity and applications thereof
GB201312737D0 (en) 2013-07-17 2013-08-28 Univ Greenwich Cyclodextrin
CA2919892C (en) 2013-08-12 2019-06-18 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
DK3169315T3 (da) 2014-07-17 2020-08-10 Pharmaceutical Manufacturing Res Services In Væskefyldt doseringsform til forhindring af misbrug med øjeblikkelig frigivelse
JP6914188B2 (ja) 2014-08-22 2021-08-04 サイデックス・ファーマシューティカルズ・インコーポレイテッド 分画アルキル化シクロデキストリン組成物ならびにその調製方法および使用方法
EP3193879A4 (en) * 2014-09-17 2018-05-16 Epizyme, Inc. Injectable formulations for treating cancer
EP3209282A4 (en) 2014-10-20 2018-05-23 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
KR102465027B1 (ko) * 2015-02-10 2022-11-09 액섬 테라퓨틱스, 인크. 멜록시캄을 포함하는 약학 조성물
US10976232B2 (en) 2015-08-24 2021-04-13 Gpb Scientific, Inc. Methods and devices for multi-step cell purification and concentration
WO2017035262A1 (en) * 2015-08-24 2017-03-02 Gpb Scientific, Llc Methods and devices for multi-step cell purification and concentration
AU2017361129B2 (en) * 2016-11-18 2023-11-09 The Kids Research Institute Australia Taste masking product
AU2017374450B2 (en) * 2016-12-14 2023-05-11 Sk Biopharmaceuticals Co., Ltd. Parenteral liquid preparation comprising carbamate compound
EP4650374A2 (en) * 2017-05-10 2025-11-19 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
WO2018234565A1 (en) 2017-06-23 2018-12-27 Chiesi Farmaceutici S.P.A. Method of preventing of systemic-to-pulmonary-artery shunt thrombosis
CN110711180B (zh) * 2018-07-13 2022-03-29 武汉武药科技有限公司 一种替格瑞洛组合物及其制备方法
WO2020101627A1 (en) * 2018-11-14 2020-05-22 Canakkale Onsekiz Mart Universitesi Rektorlugu A solution developed to be applied to the saphenous vein graft
US12403120B2 (en) 2018-12-10 2025-09-02 Sq Innovation Ag Pharmaceutical compositions of furosemide and uses thereof
US12397005B2 (en) 2019-01-04 2025-08-26 Sq Innovation Ag Pharmaceutical compositions of torsemide and uses thereof
US11246851B2 (en) 2019-01-04 2022-02-15 Sq Innovation Ag Pharmaceutical compositions of furosemide and uses thereof
CN109674744B (zh) * 2019-01-21 2021-09-17 成都欣捷高新技术开发股份有限公司 稳定的盐酸替罗非班液体组合物及其制备方法
US11992514B2 (en) 2019-05-20 2024-05-28 MAIA Pharmaceuticals, Inc. Ready-to-use bivalirudin compositions
US11739952B2 (en) 2020-07-13 2023-08-29 Rheem Manufacturing Company Integrated space conditioning and water heating/cooling systems and methods thereto
WO2023012479A1 (en) 2021-08-03 2023-02-09 Liqmeds Worldwide Limited An oral pharmaceutical solution of clopidogrel
WO2023123468A1 (zh) * 2021-12-31 2023-07-06 杭州奥默医药股份有限公司 心脑血管药物及其应用
TW202339745A (zh) * 2022-01-28 2023-10-16 大陸商上海柯君醫藥科技有限公司 抗血小板藥物的藥物組合物及其用途
CN115902237B (zh) * 2022-11-09 2024-09-27 哈尔滨医科大学 用于判断急性心肌梗死后心源性猝死的生物标志物及其应用
WO2024234014A1 (en) * 2023-05-11 2024-11-14 Spiritus Bioscience, Inc. Sublingual spray formulations of psychedelics

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3426011A (en) * 1967-02-13 1969-02-04 Corn Products Co Cyclodextrins with anionic properties
FR2530247B1 (fr) 1982-07-13 1986-05-16 Sanofi Sa Nouveaux derives de la thieno (3, 2-c) pyridine, leur procede de preparation et leur application therapeutique
FR2623810B2 (fr) 1987-02-17 1992-01-24 Sanofi Sa Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant
US4927013A (en) * 1989-04-12 1990-05-22 Eastman Kodak Company Package for storing and remixing two materials
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5241059A (en) 1990-05-21 1993-08-31 Toppan Printing Co., Ltd. Cyclodextrin derivatives
FI101150B (fi) 1991-09-09 1998-04-30 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
US5324718A (en) 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
US5472954A (en) 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
US5576328A (en) * 1994-01-31 1996-11-19 Elf Sanofi Method for the secondary prevention of ischemic events
US5632275A (en) * 1994-09-16 1997-05-27 Scribner-Browne Medical Design Incorporated Catheter lab table pad and method for using the same
FR2744918B1 (fr) * 1996-02-19 1998-05-07 Sanofi Sa Nouvelles associations de principes actifs contenant un derive de thieno(3,2-c)pyridine et un antithrombotique
FR2751540B1 (fr) * 1996-07-26 1998-10-16 Sanofi Sa Composition pharmaceutique antithrombotique
US5916883A (en) 1996-11-01 1999-06-29 Poly-Med, Inc. Acylated cyclodextrin derivatives
US5874418A (en) 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
EA199901112A1 (ru) 1997-06-05 2000-06-26 Эли Лилли Энд Компани Способы лечения тромботических нарушений
ES2210769T3 (es) 1997-06-13 2004-07-01 Cydex Inc. Compuesto con vida de almacenamiento prolongada que comprende ciclodextrina y medicamentos y promedicamentos que se descomponen en componentes insolubles en agua.
ATE323110T1 (de) * 1997-07-01 2006-04-15 Pfizer Prod Inc Verfahren zur herstellung von einem cyclodextrin
US20010044584A1 (en) 1997-08-28 2001-11-22 Kensey Kenneth R. In vivo delivery methods and compositions
FR2769313B1 (fr) * 1997-10-06 2000-04-21 Sanofi Sa Derives d'esters hydroxyacetiques, leur procede de preparation et leur utilisation comme intermediaires de synthese
AU759280C (en) 1998-02-23 2004-01-22 Cyclops, Ehf High-energy cyclodextrin complexes
FR2779726B1 (fr) * 1998-06-15 2001-05-18 Sanofi Sa Forme polymorphe de l'hydrogenosulfate de clopidogrel
CA2332608C (en) 1998-06-17 2010-03-23 Bristol-Myers Squibb Company Preventing cerebral infarction through administration of adp-receptor antiplatelet and antihypertensive drugs in combination
DE19836021A1 (de) 1998-08-10 2000-03-09 Weitmann & Konrad Fa Pudervorrichtung
US6509348B1 (en) * 1998-11-03 2003-01-21 Bristol-Myers Squibb Company Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination
US6761903B2 (en) 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US20030104048A1 (en) 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
EP1298132B1 (en) 2000-07-06 2006-11-22 Sankyo Company, Limited Hydropyridine derivative acid addition salts
JP4874482B2 (ja) 2000-12-25 2012-02-15 第一三共株式会社 アスピリンを含有する医薬組成物
CN100341506C (zh) 2000-12-25 2007-10-10 三共株式会社 含有阿斯匹林的药用组合物
US7034013B2 (en) 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
US20080220441A1 (en) * 2001-05-16 2008-09-11 Birnbaum Eva R Advanced drug development and manufacturing
MXPA03011793A (es) * 2001-06-29 2004-04-02 Maxygen Holdings Ltd Formulaciones de interferon.
CA2363053C (en) 2001-11-09 2011-01-25 Bernard Charles Sherman Clopidogrel bisulfate tablet formulation
US6767913B2 (en) * 2001-12-18 2004-07-27 Teva Pharmaceutical Industries Ltd. Crystal forms iii, iv, v, and novel amorphous form of clopidogrel hydrogensulfate, processes for their preparation, processes for the preparation of form i, compositions containing the new forms and methods of administering the new forms
US7074928B2 (en) 2002-01-11 2006-07-11 Teva Pharmaceutical Industries, Ltd. Polymorphs of clopidogrel hydrogensulfate
HUP0200438A3 (en) 2002-02-06 2003-10-28 Egis Gyogyszergyar Nyilvanosan Novel clopidogrel hydrochloride polymorphs, process for the preparation thereof, their use and pharmaceutical compositions containing them
JP2005525362A (ja) * 2002-03-01 2005-08-25 カイロン コーポレイション 虚血の処置のための方法および組成物
ITMI20020933A1 (it) * 2002-05-03 2003-11-03 Danimite Dipharma S P A Procedimento per la sintesi di clopidogrel
US20040043052A1 (en) * 2002-05-24 2004-03-04 Angiotech Pharmaceuticals, Inc. Compositions and methods for coating medical implants
IL166593A0 (en) 2002-08-02 2006-01-15 Racemization and enantiomer separation of clopidogrel
US6800759B2 (en) * 2002-08-02 2004-10-05 Teva Pharmaceutical Industries Ltd. Racemization and enantiomer separation of clopidogrel
CZ297472B6 (cs) 2002-08-27 2006-12-13 Zentiva, A.S. Zpusob výroby clopidogrelu hydrogensulfátu krystalické formy I
WO2004024126A1 (en) 2002-09-13 2004-03-25 Cydex, Inc. Capsules containing aqueous fill compositions stabilized with derivatized cyclodextrin
AU2003270861A1 (en) 2002-10-02 2004-04-23 Bristol-Myers Squibb Company Novel combination of a factor xa inhibitor and clopidogrel
CN1717209A (zh) 2002-10-09 2006-01-04 植入疗法公司 以环糊精为基础的材料、其相关的组合物和用途
US20040115287A1 (en) 2002-12-17 2004-06-17 Lipocine, Inc. Hydrophobic active agent compositions and methods
DE10305984A1 (de) * 2003-02-13 2004-09-02 Helm Ag Salze organischer Säuren mit Clopidogrel und deren Verwendung zur Herstellung phamazeutischer Formulierungen
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
WO2004081015A1 (en) * 2003-03-10 2004-09-23 Hetero Drugs Limited Amorphous clopidogrel hydrogen sulfate
EP1603920A1 (en) * 2003-03-12 2005-12-14 Cadila Healthcare Ltd. Polymorph and amorphous form of (s)-(+)-clopidogrel bisulfate
US6858734B2 (en) 2003-04-23 2005-02-22 Rhodia Pharma Solutions Inc. Preparation of (S)-Clopidogrel and related compounds
JP2006525328A (ja) 2003-05-05 2006-11-09 イーライ リリー アンド カンパニー 心疾患の治療方法
AU2003249492A1 (en) * 2003-07-24 2005-02-14 Eswaran Krishnan Iyer Oral compositions for treatment of diseases
US20060003002A1 (en) 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
US20050096365A1 (en) 2003-11-03 2005-05-05 David Fikstad Pharmaceutical compositions with synchronized solubilizer release
JP2007517069A (ja) * 2003-12-31 2007-06-28 サイデックス・インコーポレイテッド スルホアルキルエーテルγ−シクロデキストリンおよびコルチコステロイドを含む吸入製剤
US20070020196A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension
SI21748A (sl) 2004-03-26 2005-10-31 Diagen D.O.O. Inkluzijski kompleksi klopidogrela in njegovih kislinskih adicijskih soli, postopek za njihovo pripravo, farmacevtski pripravki, ki vsebujejo te komplekse in njihova uporaba za zdravljenje tromboze
BRPI0418726A (pt) * 2004-04-09 2007-09-11 Hanmi Pharm Ind Co Ltd naftalenossulfonato de clopidogrel cristalino ou hidrato do mesmo, método para sua preparação e composição farmacêutica contendo o mesmo
MXPA06012777A (es) * 2004-05-06 2007-02-14 Cydex Inc Formulaciones de sabor enmascarado que contienen sertralina y eter sulfoalquilico-ciclodextrina.
US8128954B2 (en) 2004-06-07 2012-03-06 California Institute Of Technology Biodegradable drug-polymer delivery system
US20060047121A1 (en) * 2004-09-01 2006-03-02 Sawant Kamlesh D Novel process for preparation of clopidogrel bisulfate polymorph - Form I
KR20070052780A (ko) 2004-09-21 2007-05-22 테바 파마슈티컬 인더스트리즈 리미티드 결정질 클로피도그렐 브롬산염 및 이의 제조 방법
US7446200B2 (en) 2004-10-04 2008-11-04 Usv, Ltd. Rapid resolution process of clopidogrel base and a process for preparation of clopidogrel bisulfate polymorph-form I
JP2008526896A (ja) 2005-02-24 2008-07-24 テバ ファーマシューティカル インダストリーズ リミティド 医薬製剤に適したグロピドグレル塩基及びその調製
TWI318571B (en) 2005-06-10 2009-12-21 Lilly Co Eli Formulation of a thienopyridine platelet aggregation inhibitor
US20070003615A1 (en) * 2005-06-13 2007-01-04 Elan Pharma International Limited Nanoparticulate clopidogrel and aspirin combination formulations
CN101198329A (zh) 2005-06-17 2008-06-11 伊莱利利公司 普拉格雷给药方案
EP1898922A4 (en) * 2005-07-04 2012-03-14 Ramu Krishnan MEDICINE OR IMPROVED PHARMACEUTICAL COMPOUNDS AND PREPARATION THEREOF
EP1940399A2 (en) 2005-08-19 2008-07-09 Eli Lilly & Company Use of par-i/par- 4 inhibitors for treating or preventing vascular diseases
KR100783286B1 (ko) * 2005-09-26 2007-12-06 주식회사종근당 클로피도그렐 우선성 광학이성체의 유리염기를 함유하는고형의 약제학적 조성물
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
CN100503647C (zh) 2005-11-02 2009-06-24 南京师范大学 羟丙基-磺丁基-β-环糊精及其制备方法、分析方法以及在药学上的应用
US7658913B2 (en) * 2005-11-28 2010-02-09 Verrow Pharmaceuticals, Inc. Compositions useful for reducing nephrotoxicity and methods of use thereof
WO2008060934A2 (en) 2006-11-14 2008-05-22 Acusphere, Inc. Formulations of tetrahydropyridine antiplatelet agents for parenteral or oral administration
CN101568339A (zh) 2006-12-07 2009-10-28 伊莱利利公司 普拉格雷的制品
KR20080055356A (ko) 2006-12-15 2008-06-19 에스케이케미칼주식회사 보관안정성이 우수한 클로피도그렐 함유 포접 복합체
KR20080055355A (ko) 2006-12-15 2008-06-19 에스케이케미칼주식회사 보관안정성이 우수한 클로피도그렐 함유 포접 복합체
JP5363307B2 (ja) 2007-03-02 2013-12-11 第一三共株式会社 高純度のプラスグレル塩酸塩の製造方法
RU2470636C2 (ru) 2007-04-27 2012-12-27 Сайдекс Фамэсьютиклз, Инк. Композиция клопидогреля и сульфоалкилового эфира циклодекстрина (варианты) и способы лечения заболеваний посредством названной композиции (варианты)
WO2009018069A2 (en) 2007-07-30 2009-02-05 Cydex Pharmaceuticals, Inc Mixtures of cyclodextrin derivatives
JP5137961B2 (ja) 2007-10-22 2013-02-06 株式会社アドバンテスト 周波数変換装置および直交変調器
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
CA2730995C (en) 2008-07-17 2016-11-22 Micell Technologies, Inc. Drug delivery medical device
JP2011529859A (ja) 2008-08-02 2011-12-15 ルナン ファーマシューティカル グループ コーポレーション プラスグレル重硫酸塩及びその薬物組成物並びにその応用
CN101390856B (zh) 2008-11-10 2011-04-20 重庆莱美药业股份有限公司 氯吡格雷的固体制剂及其制备方法
DK3100728T3 (da) 2009-05-13 2020-02-17 Cydex Pharmaceuticals Inc Farmaceutiske sammensætninger omfattende prasugrel og cyclodextrin-derivativ og fremgangsmåder til fremstilling og brug af samme
CN102232949A (zh) 2010-04-27 2011-11-09 孙远 提高药物溶出度的组合物及其制备方法

Also Published As

Publication number Publication date
US20100292268A1 (en) 2010-11-18
JP2017061533A (ja) 2017-03-30
JP6228286B2 (ja) 2017-11-08
US8343995B2 (en) 2013-01-01
US20170173178A1 (en) 2017-06-22
AU2008245550A1 (en) 2008-11-06
NZ581362A (en) 2011-07-29
EP2152078B8 (en) 2021-03-17
RU2470636C2 (ru) 2012-12-27
KR20150041173A (ko) 2015-04-15
CA2685331C (en) 2016-07-05
CN101686681A (zh) 2010-03-31
CA2921601C (en) 2018-04-24
CA2685331A1 (en) 2008-11-06
US20160058786A1 (en) 2016-03-03
CN104800210B (zh) 2019-08-06
IL201776A (en) 2016-05-31
US20180326090A1 (en) 2018-11-15
JP6496381B2 (ja) 2019-04-03
ES2855700T3 (es) 2021-09-24
CA2921601A1 (en) 2008-11-06
EP3766493A1 (en) 2021-01-20
HUE053158T2 (hu) 2021-06-28
BRPI0809838A2 (pt) 2019-01-15
WO2008134601A1 (en) 2008-11-06
US20130129700A1 (en) 2013-05-23
KR20160033792A (ko) 2016-03-28
KR20100017366A (ko) 2010-02-16
DK2152078T3 (da) 2021-02-08
EP2152078A1 (en) 2010-02-17
HK1212909A1 (zh) 2016-06-24
IL201776A0 (en) 2010-06-16
JP6076382B2 (ja) 2017-02-08
AU2008245550B2 (en) 2013-10-10
US20150025243A1 (en) 2015-01-22
RU2009143991A (ru) 2011-06-10
WO2008134600A1 (en) 2008-11-06
JP2015091857A (ja) 2015-05-14
JP2018021071A (ja) 2018-02-08
JP2010525083A (ja) 2010-07-22
EP3766493B1 (en) 2023-08-23
US9125945B2 (en) 2015-09-08
BRPI0809838B1 (pt) 2021-10-05
CN101686681B (zh) 2015-04-01
KR101753131B1 (ko) 2017-07-04
US10034947B2 (en) 2018-07-31
JP5681485B2 (ja) 2015-03-11
CN104800210A (zh) 2015-07-29
US9623045B2 (en) 2017-04-18
EP2152078A4 (en) 2011-06-15
US10512697B2 (en) 2019-12-24
US8853236B2 (en) 2014-10-07
EP2152078B1 (en) 2021-01-13
SI2152078T1 (sl) 2021-08-31

Similar Documents

Publication Publication Date Title
MX2009011619A (es) Formulaciones que contienen clopidogrel y eter sulfoalquilico-ciclodextrina y metodos de uso.
MX346879B (es) Formulaciones de ketorolaco listas para su uso.
MX2009010878A (es) Pastilla de melatonina y metodos de preparacion y uso.
MX2010003923A (es) Formulacion farmaceutica de valsartan.
TW200738241A (en) Pyridazine derivatives
MX2009008935A (es) Moduladores de las propiedades farmacocineticas de productos terapeuticos.
WO2010039762A3 (en) Pharmaceutical compositions comprising boronic acid compounds
MX2010005824A (es) Derivados de aminotiazol.
MY160728A (en) Morpholinothiazoles as alpha 7 positive allosteric modulators
EA201071288A1 (ru) Тризамещенные пиразолы в качестве модуляторов рецепторов ацетилхолина
HRP20090077B1 (hr) Modulatori farmakokinetičkih svojstava terapeutika
MX2008016426A (es) Derivados de alquilpiridazina como inhibidores de 11 beta hidroxiesteroide deshidrogenasa tipo 1(11b-hsd 1).
MX2011012639A (es) Sales de derivados de pirazolon azo sustituidos con biciclo, metodo de preparacion y uso de los mismos.
WO2008006795A3 (en) Indole compounds
MX2009012523A (es) Composiciones utiles para reducir la nefrotoxicidad y metodos para utilizarlas.
TNSN07337A1 (en) Pharmaceutical composition comprising an indolylmaleimide derivative
IN2012DN01232A (es)
WO2011037976A3 (en) Pramipexole pharmaceutical formulations
MX2009003169A (es) Derivados de sulfonamida.
TW200740764A (en) Pyrazolone derivatives
UA94251C2 (ru) Индолпроизводная соль лимонной кислоты и ее фармацевтическое применение
MX2010003112A (es) Formas de dosificacion solubles que contienen derivados de cephem adecuados para administracion parenteral.
MX2009001572A (es) Derivados de arilpiperazina y usos de los mismos.
WO2009079679A3 (de) Pharmazeutische zusammensetzung zur parenteralen verabreichung eines ultrakurzwirksamξn beta-adrenorezeptor antagonisten
TWI455711B (zh) 用以抑制前驅蝕骨細胞生長之醫藥組合物

Legal Events

Date Code Title Description
FG Grant or registration